Beta-2-adrenoceptor-mediated	beta-2-adrenoceptor-mediated	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
and	and	O	O	O	O
its	its	O	O	O	O
abolishment	abolishment	O	O	O	O
by	by	O	O	O	O
oxprenolol	oxprenolol	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
time	time	O	O	O	O
course	course	O	O	O	O
and	and	O	O	O	O
concentration-effect	concentration-effect	O	O	O	O
relationship	relationship	O	O	O	O
of	of	O	O	O	O
terbutaline-induced	terbutaline-induced	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
was	was	O	O	O	O
studied	studied	O	O	O	O
,	,	O	O	O	O
using	using	O	O	O	O
computer-aided	computer-aided	O	O	O	O
pharmacokinetic-dynamic	pharmacokinetic-dynamic	O	O	O	O
modeling	modeling	O	O	O	O
.	.	O	O	O	O

Subsequently	subsequently	O	O	O	O
we	we	O	O	O	O
investigated	investigated	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
oxprenolol	oxprenolol	O	O	OTHERS	I
in	in	O	O	O	O
antagonizing	antagonizing	O	O	O	O
such	such	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
,	,	O	O	O	O
together	together	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
pharmacokinetic	pharmacokinetic	O	O	O	O
interaction	interaction	O	O	O	O
between	between	O	O	O	O
both	both	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

Six	six	O	O	O	O
healthy	healthy	O	O	O	O
subjects	subjects	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
a	a	O	O	O	O
0.5	0.5	O	O	O	O
mg	mg	O	O	OTHERS	I
subcutaneous	subcutaneous	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
terbutaline	terbutaline	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
two	two	O	O	O	O
occasions	occasions	O	O	O	O
:	:	O	O	O	O
1	1	O	O	O	O
hour	hour	O	O	O	O
after	after	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
placebo	placebo	O	O	O	O
and	and	O	O	O	O
1	1	O	O	O	O
hour	hour	O	O	O	O
after	after	O	O	O	O
80	80	O	O	O	O
mg	mg	O	O	OTHERS	I
oxprenolol	oxprenolol	O	O	OTHERS	I
orally	orally	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
7-hour	7-hour	O	O	O	O
period	period	O	O	O	O
after	after	O	O	O	O
terbutaline	terbutaline	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
,	,	O	O	O	O
plasma	plasma	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
taken	taken	O	O	O	O
for	for	O	O	O	O
determination	determination	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
and	and	O	O	O	O
drug	drug	O	O	O	O
concentrations	concentrations	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
sigmoid	sigmoid	O	O	O	O
Emax	emax	O	O	O	O
model	model	O	O	O	O
offered	offered	O	O	O	O
a	a	O	O	O	O
good	good	O	O	O	O
description	description	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
relation	relation	O	O	O	O
between	between	O	O	O	O
terbutaline	terbutaline	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
and	and	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
effects	effects	O	O	O	O
.	.	O	O	O	O

Oxprenolol	oxprenolol	O	O	OTHERS	I
caused	caused	O	O	O	O
decreases	decreases	O	O	O	O
of	of	O	O	O	O
65	65	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
56	56	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
terbutaline	terbutaline	CHEMICALS	O	OTHERS	I
volume	volume	O	O	O	O
of	of	O	O	O	O
distribution	distribution	O	O	O	O
and	and	O	O	O	O
clearance	clearance	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
130	130	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
its	its	O	O	O	O
AUC	auc	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
spite	spite	O	O	O	O
of	of	O	O	O	O
higher	higher	O	O	O	O
terbutaline	terbutaline	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
after	after	O	O	O	O
oxprenolol	oxprenolol	O	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
was	was	O	O	O	O
almost	almost	O	O	O	O
completely	completely	O	O	O	O
antagonized	antagonized	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
beta	beta	O	O	O	O
2-blocking	2-blocking	O	O	O	O
action	action	O	O	O	O
.	.	O	O	O	O

